Heritage Trust Co lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 43,762 shares of the biopharmaceutical company’s stock after selling 223 shares during the period. Heritage Trust Co’s holdings in Gilead Sciences were worth $3,272,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of GILD. Candriam Luxembourg S.C.A. lifted its position in shares of Gilead Sciences by 0.4% during the fourth quarter. Candriam Luxembourg S.C.A. now owns 2,256,962 shares of the biopharmaceutical company’s stock worth $146,658,000 after acquiring an additional 10,067 shares in the last quarter. RFG Advisory LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth $208,000. Clarius Group LLC increased its holdings in shares of Gilead Sciences by 7.6% in the fourth quarter. Clarius Group LLC now owns 8,082 shares of the biopharmaceutical company’s stock worth $518,000 after purchasing an additional 572 shares during the period. Tompkins Financial Corp increased its holdings in shares of Gilead Sciences by 903.5% in the fourth quarter. Tompkins Financial Corp now owns 1,144 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 1,030 shares during the period. Finally, Ballentine Partners LLC increased its holdings in shares of Gilead Sciences by 3.7% in the fourth quarter. Ballentine Partners LLC now owns 5,682 shares of the biopharmaceutical company’s stock worth $369,000 after purchasing an additional 203 shares during the period. Hedge funds and other institutional investors own 77.34% of the company’s stock.
NASDAQ GILD traded down $0.36 during trading on Friday, hitting $73.14. 3,702,714 shares of the company’s stock traded hands, compared to its average volume of 22,051,432. The stock has a fifty day moving average of $77.81 and a two-hundred day moving average of $70.11. The company has a debt-to-equity ratio of 1.00, a current ratio of 3.04 and a quick ratio of 2.92. Gilead Sciences, Inc. has a 12-month low of $60.89 and a 12-month high of $85.97. The firm has a market cap of $91.85 billion, a P/E ratio of 18.82, a PEG ratio of 3.16 and a beta of 0.72.
The company also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Friday, June 12th will be issued a dividend of $0.68 per share. The ex-dividend date is Thursday, June 11th. This represents a $2.72 dividend on an annualized basis and a dividend yield of 3.72%. Gilead Sciences’s dividend payout ratio is currently 44.30%.
In other news, EVP Brett A. Pletcher sold 13,210 shares of the stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $79.23, for a total transaction of $1,046,628.30. Following the completion of the sale, the executive vice president now directly owns 27,204 shares in the company, valued at $2,155,372.92. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Diane E. Wilfong sold 12,264 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $80.09, for a total transaction of $982,223.76. Following the sale, the chief accounting officer now owns 23,685 shares of the company’s stock, valued at $1,896,931.65. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 60,585 shares of company stock valued at $4,671,283. 0.13% of the stock is currently owned by company insiders.
Several research firms have recently weighed in on GILD. Credit Suisse Group reaffirmed a “sell” rating and issued a $60.00 price target on shares of Gilead Sciences in a report on Friday, April 17th. Wells Fargo & Co reaffirmed a “hold” rating and issued a $84.00 price target on shares of Gilead Sciences in a report on Friday, May 1st. Barclays began coverage on shares of Gilead Sciences in a report on Thursday, February 27th. They issued an “underweight” rating and a $62.00 price target on the stock. JPMorgan Chase & Co. reaffirmed a “hold” rating and issued a $85.00 price target on shares of Gilead Sciences in a report on Wednesday, May 13th. Finally, TheStreet raised Gilead Sciences from a “c” rating to a “b-” rating in a research note on Friday, February 21st. Seven equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and nine have given a buy rating to the company’s stock. Gilead Sciences presently has an average rating of “Hold” and an average target price of $78.15.
Gilead Sciences Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.